UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 39

Sortiert nach

Six-2 glomerular expression for the prediction of renal outcome in systemic amyloidosis

Amyloid, 2019-03, Vol.26 (sup1), p.97-98

2019

Volltextzugriff (PDF)

Sars-Cov-2 Infection and Systemic Light Chain Amyloidosis: The International Society of Amyloidosis' Survey

Blood, 2020-11, Vol.136 (Supplement 1), p.11-11

2020

Volltextzugriff (PDF)

Evolving Pattern Improves the IMWG 2/20/20 Classification for Patients with Smoldering Multiple Myeloma

Blood, 2022-11, Vol.140 (Supplement 1), p.4341-4342

2022

Volltextzugriff (PDF)

Immunoparesis Defined By Heavy/Light Chain Pair Suppression in Smoldering Multiple Myeloma Patients Shows Isotype Specificity

Blood, 2020-11, Vol.136 (Supplement 1), p.2-3

2020

Volltextzugriff (PDF)

Prognostic Impact of MYD88 L265P Mutation By Droplet Digital PCR in IgM MGUS and Smoldering Waldenström Macroglobulinemia

Blood, 2021-11, Vol.138 (Supplement 1), p.462-462

2021

Volltextzugriff (PDF)

Bicistronic CAR T Cell Against CD229 and BCMA Effectively Controls Multiple Myeloma

Blood, 2022-11, Vol.140 (Supplement 1), p.10281-10282

2022

Volltextzugriff (PDF)

MO929KIDNEY TRANSPLANTATION IN MONOCLONAL IMMUNOGLOBULIN DEPOSITION DISEASE: A REPORT OF 6 CASES

Nephrology, dialysis, transplantation, 2021-05, Vol.36 (Supplement_1)

2021

Volltextzugriff (PDF)

First Glimpse on Real-World Efficacy Outcomes for 2000 Patients with Systemic Light Chain Amyloidosis in Europe: A Retrospective Observational Multicenter Study By the European Myeloma Network

Blood, 2020-11, Vol.136 (Supplement 1), p.50-51

2020

Volltextzugriff (PDF)

Graded Cardiac Response Criteria for AL Amyloidosis: The Impact of Depth of Cardiac Response on Survival

Blood, 2021-11, Vol.138 (Supplement 1), p.2720-2720

2021

Volltextzugriff (PDF)

Systemic Light Chain Amyloidosis across Europe: Key Outcomes from a Retrospective Study of 4500 Patients

Blood, 2021-11, Vol.138 (Supplement 1), p.153-153

2021

Volltextzugriff (PDF)

Graded Renal Response Criteria for Light Chain (AL) Amyloidosis

Blood, 2021-11, Vol.138 (Supplement 1), p.2721-2721

2021

Volltextzugriff (PDF)

P-155: Paraskeletal and extramedullary plasmacytomas in multiple myeloma at diagnosis and at first relapse: 49-years experience from an academic institution

Clinical lymphoma, myeloma and leukemia, 2022-08, Vol.22, p.S120

2022

Volltextzugriff (PDF)

OP201: A Phase 1/2 Study of Melflufen and Dexamethasone in Patients with Immunoglobulin Light Chain (AL) Amyloidosis

Blood, 2019-11, Vol.134 (Supplement_1), p.3163-3163

2019

Volltextzugriff (PDF)

P-154: Incidence and prognosis of renal failure in multiple myeloma: 50-years experience from an academic institution

Clinical lymphoma, myeloma and leukemia, 2022-08, Vol.22, p.S119-S120

2022

Volltextzugriff (PDF)

Reduction in Absolute Involved Free Light Chain and Difference between Involved and Uninvolved Free Light Chain Is Associated with Prolonged Major Organ Deterioration Progression-Free Survival in Patients with Newly Diagnosed AL Amyloidosis Receiving Bortezomib, Cyclophosphamide, and Dexamethasone with or without Daratumumab: Results from Andromeda

Blood, 2020-11, Vol.136 (Supplement 1), p.48-50

2020

Volltextzugriff (PDF)

Extramedullary multiple myeloma escapes the effect of thalidomide

Haematologica (Roma), 2004-07, Vol.89 (7), p.832

2004

Volltextzugriff (PDF)

Plasmacytomas in Multiple Myeloma: 45-Years Experience from a Single Institution

Clinical lymphoma, myeloma and leukemia, 2017-02, Vol.17 (1), p.e107-e107

2017

Volltextzugriff (PDF)

Efficacy of Novel Agents on Soft-tissue Plasmacytomas in Patients with Relapsed Multiple Myeloma

Clinical lymphoma, myeloma and leukemia, 2017-02, Vol.17 (1), p.e128-e128

2017

Volltextzugriff (PDF)

Miopatía amiloidea como causa de insuficiencia respiratoria

Medicina clínica, 2016-03, Vol.146 (5), p.e25-e26

2016

Volltextzugriff (PDF)

Impact of Evolving Pattern in Early Progression of Patients With Smoldering Multiple Myeloma

Clinical lymphoma, myeloma and leukemia, 2017-02, Vol.17 (1), p.e23-e24

2017

Volltextzugriff (PDF)

Respiratory failure caused by amyloid myopathy

Medicina clínica (English ed.), 2016-03, Vol.146 (5), p.e25-e26

2016

Volltextzugriff (PDF)

Respiratory failure caused by amyloid myopathy

Medicina clinica, 2016-03, Vol.146 (5), p.e25

2016

Volltextzugriff (PDF)

Phase II Trial of Cyclophosphamide, Lenalidomide and Dexamethasone (CYCLO-LEN-DEX) for Previously Untreated Patients with Light-Chain Amyloidosis (AL)

Blood, 2014-12, Vol.124 (21), p.2135-2135

2014

Volltextzugriff (PDF)

1 – 25 von 39

Suche als RSS-Feed

Aktive Filter

Zeitschrift / SerieClinical Lymphoma & Myeloma

ThemaScience & Technology

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(35)
Mit Volltextzugriff
(36)

Publikationsform

Artikel
(36)
Berichte
(3)

Sprache

Englisch
(37)
Spanisch
(2)

Erscheinungsjahr

n.n

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Six-2 glomerular expression for the prediction of renal outcome in systemic amyloidosis

Sars-Cov-2 Infection and Systemic Light Chain Amyloidosis: The International Society of Amyloidosis' Survey

Evolving Pattern Improves the IMWG 2/20/20 Classification for Patients with Smoldering Multiple Myeloma

Immunoparesis Defined By Heavy/Light Chain Pair Suppression in Smoldering Multiple Myeloma Patients Shows Isotype Specificity

Prognostic Impact of MYD88 L265P Mutation By Droplet Digital PCR in IgM MGUS and Smoldering Waldenström Macroglobulinemia

Bicistronic CAR T Cell Against CD229 and BCMA Effectively Controls Multiple Myeloma

MO929KIDNEY TRANSPLANTATION IN MONOCLONAL IMMUNOGLOBULIN DEPOSITION DISEASE: A REPORT OF 6 CASES

First Glimpse on Real-World Efficacy Outcomes for 2000 Patients with Systemic Light Chain Amyloidosis in Europe: A Retrospective Observational Multicenter Study By the European Myeloma Network

Graded Cardiac Response Criteria for AL Amyloidosis: The Impact of Depth of Cardiac Response on Survival

Subcutaneous Daratumumab with Bortezomib, Cyclophosphamide, and Dexamethasone in Patients with Newly Diagnosed Light Chain (AL) Amyloidosis: 18-Month Analysis of the Phase 3 ANDROMEDA Study

Systemic Light Chain Amyloidosis across Europe: Key Outcomes from a Retrospective Study of 4500 Patients

Graded Renal Response Criteria for Light Chain (AL) Amyloidosis

P-155: Paraskeletal and extramedullary plasmacytomas in multiple myeloma at diagnosis and at first relapse: 49-years experience from an academic institution

OP201: A Phase 1/2 Study of Melflufen and Dexamethasone in Patients with Immunoglobulin Light Chain (AL) Amyloidosis

P-154: Incidence and prognosis of renal failure in multiple myeloma: 50-years experience from an academic institution

Health-Related Quality of Life in Patients with AL Amyloidosis Treated with Daratumumab, Bortezomib, Cyclophosphamide, and Dexamethasone: Results from the Phase 3 Andromeda Study

Extramedullary multiple myeloma escapes the effect of thalidomide

Plasmacytomas in Multiple Myeloma: 45-Years Experience from a Single Institution

Efficacy of Novel Agents on Soft-tissue Plasmacytomas in Patients with Relapsed Multiple Myeloma

Miopatía amiloidea como causa de insuficiencia respiratoria

Impact of Evolving Pattern in Early Progression of Patients With Smoldering Multiple Myeloma

Respiratory failure caused by amyloid myopathy

Respiratory failure caused by amyloid myopathy

Phase II Trial of Cyclophosphamide, Lenalidomide and Dexamethasone (CYCLO-LEN-DEX) for Previously Untreated Patients with Light-Chain Amyloidosis (AL)

Aktive Filter

Suchergebnisse filtern